121. Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
作者: Choong Tat Keng.;Ching Wooen Sze.;Dahai Zheng.;Zhiqiang Zheng.;Kylie Su Mei Yong.;Shu Qi Tan.;Jessica Jie Ying Ong.;Sue Yee Tan.;Eva Loh.;Megha Haridas Upadya.;Chik Hong Kuick.;Hak Hotta.;Seng Gee Lim.;Thiam Chye Tan.;Kenneth T E Chang.;Wanjin Hong.;Jianzhu Chen.;Yee-Joo Tan.;Qingfeng Chen.
来源: Gut. 2016年65卷10期1744-53页
HCV infection affects millions of people worldwide, and many patients develop chronic infection leading to liver cancers. For decades, the lack of a small animal model that can recapitulate HCV infection, its immunopathogenesis and disease progression has impeded the development of an effective vaccine and therapeutics. We aim to provide a humanised mouse model for the understanding of HCV-specific human immune responses and HCV-associated disease pathologies.
123. Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis.
作者: L Ichou.;N Carbonell.;P E Rautou.;L Laurans.;S Bourcier.;C Pichereau.;J L Baudel.;J B Nousbaum.;C Renou.;R Anty.;J Tankovic.;E Maury.;B Guidet.;L Landraud.;H Ait-Oufella.
来源: Gut. 2016年65卷3期536-8页 124. Genome-wide association study of gastric adenocarcinoma in Asia: a comparison of associations between cardia and non-cardia tumours.
作者: Nan Hu.;Zhaoming Wang.;Xin Song.;Lixuan Wei.;Byung Sik Kim.;Neal D Freedman.;Jiwon Baek.;Laurie Burdette.;Jiang Chang.;Charles Chung.;Sanford M Dawsey.;Ti Ding.;Yu-Tang Gao.;Carol Giffen.;Yaling Han.;Myunghee Hong.;Jia Huang.;Hee Sung Kim.;Woon-Puay Koh.;Linda M Liao.;Yi Min Mao.;You-Lin Qiao.;Xiao-Ou Shu.;Wen Tan.;Chaoyu Wang.;Chen Wu.;Min-Jie Wu.;Yong-Bing Xiang.;Meredith Yeager.;Jeong Hwan Yook.;Jian-Min Yuan.;Peng Zhang.;Xue-Ke Zhao.;Wei Zheng.;Kyuyoung Song.;Li-Dong Wang.;Dongxin Lin.;Stephen J Chanock.;Alisa M Goldstein.;Philip R Taylor.;Christian C Abnet.
来源: Gut. 2016年65卷10期1611-8页
Genome-wide association studies (GWAS) of gastric cancer have reported differences in single-nucleotide polymorphism (SNP) associations for tumour subtypes, particularly when divided by location into the gastric cardia versus the non-cardia.
125. Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome.
作者: François Cauchy.;Mouniya Mebarki.;Miguel Albuquerque.;Samira Laouirem.;Pierre Emmanuel Rautou.;Olivier Soubrane.;Eric Raymond.;Pierre Bedossa.;Valérie Paradis.
来源: Gut. 2015年64卷9期1498-500页 126. Tablet computer-based multimedia enhanced medical training improves performance in gastroenterology and endoscopy board style exam compared with traditional medical education.128. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
作者: Heiko Pohl.;Oliver Pech.;Haris Arash.;Manfred Stolte.;Hendrik Manner.;Andrea May.;Klaus Kraywinkel.;Amnon Sonnenberg.;Christian Ell.
来源: Gut. 2016年65卷2期196-201页
Although it is well understood that the risk of oesophageal adenocarcinoma increases with Barrett length, transition risks for cancer associated with different Barrett lengths are unknown. We aimed to estimate annual cancer transition rates for patients with long-segment (≥3 cm), short-segment (≥1 to <3 cm) and ultra-short-segment (<1 cm) Barrett's oesophagus.
130. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.
作者: Maud Lemoine.;Yusuke Shimakawa.;Shevanthi Nayagam.;Mustapha Khalil.;Penda Suso.;Jo Lloyd.;Robert Goldin.;Harr-Freeya Njai.;Gibril Ndow.;Makie Taal.;Graham Cooke.;Umberto D'Alessandro.;Muriel Vray.;Papa Saliou Mbaye.;Ramou Njie.;Vincent Mallet.;Mark Thursz.
来源: Gut. 2016年65卷8期1369-76页
Simple and inexpensive non-invasive fibrosis tests are highly needed but have been poorly studied in sub-Saharan Africa.
131. British Society of Gastroenterology/Association of Coloproctologists of Great Britain and Ireland guidelines for the management of large non-pedunculated colorectal polyps.
作者: Matthew D Rutter.;Amit Chattree.;Jamie A Barbour.;Siwan Thomas-Gibson.;Pradeep Bhandari.;Brian P Saunders.;Andrew M Veitch.;John Anderson.;Bjorn J Rembacken.;Maurice B Loughrey.;Rupert Pullan.;William V Garrett.;Gethin Lewis.;Sunil Dolwani.
来源: Gut. 2015年64卷12期1847-73页
These guidelines provide an evidence-based framework for the management of patients with large non-pedunculated colorectal polyps (LNPCPs), in addition to identifying key performance indicators (KPIs) that permit the audit of quality outcomes. These are areas not previously covered by British Society of Gastroenterology (BSG) Guidelines.A National Institute of Health and Care Excellence (NICE) compliant BSG guideline development process was used throughout and the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool was used to structure the guideline development process. A systematic review of literature was conducted for English language articles up to May 2014 concerning the assessment and management of LNPCPs. Quality of evaluated studies was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist System. Proposed recommendation statements were evaluated by each member of the Guideline Development Group (GDG) on a scale from 1 (strongly agree) to 5 (strongly disagree) with >80% agreement required for consensus to be reached. Where consensus was not reached a modified Delphi process was used to re-evaluate and modify proposed statements until consensus was reached or the statement discarded. A round table meeting was subsequently held to finalise recommendations and to evaluate the strength of evidence discussed. The GRADE tool was used to assess the strength of evidence and strength of recommendation for finalised statements.KPIs, a training framework and potential research questions for the management of LNPCPs were also developed. It is hoped that these guidelines will improve the assessment and management of LNPCPs.
132. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.
作者: Margriet R Timmer.;Pierre Martinez.;Chiu T Lau.;Wytske M Westra.;Silvia Calpe.;Agnieszka M Rygiel.;Wilda D Rosmolen.;Sybren L Meijer.;Fiebo J W Ten Kate.;Marcel G W Dijkgraaf.;Rosalie C Mallant-Hent.;Anton H J Naber.;Arnoud H A M van Oijen.;Lubbertus C Baak.;Pieter Scholten.;Clarisse J M Böhmer.;Paul Fockens.;Carlo C Maley.;Trevor A Graham.;Jacques J G H M Bergman.;Kausilia K Krishnadath.
来源: Gut. 2016年65卷10期1602-10页
The risk of developing adenocarcinoma in non-dysplastic Barrett's oesophagus is low and difficult to predict. Accurate tools for risk stratification are needed to increase the efficiency of surveillance. We aimed to develop a prediction model for progression using clinical variables and genetic markers.
133. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.
作者: Maria Carlota Dao.;Amandine Everard.;Judith Aron-Wisnewsky.;Nataliya Sokolovska.;Edi Prifti.;Eric O Verger.;Brandon D Kayser.;Florence Levenez.;Julien Chilloux.;Lesley Hoyles.; .;Marc-Emmanuel Dumas.;Salwa W Rizkalla.;Joel Doré.;Patrice D Cani.;Karine Clément.
来源: Gut. 2016年65卷3期426-36页
Individuals with obesity and type 2 diabetes differ from lean and healthy individuals in their abundance of certain gut microbial species and microbial gene richness. Abundance of Akkermansia muciniphila, a mucin-degrading bacterium, has been inversely associated with body fat mass and glucose intolerance in mice, but more evidence is needed in humans. The impact of diet and weight loss on this bacterial species is unknown. Our objective was to evaluate the association between faecal A. muciniphila abundance, faecal microbiome gene richness, diet, host characteristics, and their changes after calorie restriction (CR).
135. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
作者: Annette von Delft.;Isla S Humphreys.;Anthony Brown.;Katja Pfafferott.;Michaela Lucas.;Paul Klenerman.;Georg M Lauer.;Andrea L Cox.;Silvana Gaudieri.;Eleanor Barnes.
来源: Gut. 2016年65卷1期112-23页
Developing a vaccine that is cross-reactive between HCV genotypes requires data on T cell antigenic targets that extends beyond genotype-1. We characterised T cell immune responses against HCV genotype-3, the most common infecting genotype in the UK and Asia, and assessed within genotype and between genotype cross-reactivity.
136. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience.
作者: Phil A Hart.;Michael J Levy.;Thomas C Smyrk.;Naoki Takahashi.;Barham K Abu Dayyeh.;Jonathan E Clain.;Ferga C Gleeson.;Randall K Pearson.;Bret T Petersen.;Mark D Topazian.;Santhi S Vege.;Lizhi Zhang.;Suresh T Chari.
来源: Gut. 2016年65卷10期1702-9页
Idiopathic duct-centric chronic pancreatitis (IDCP), also known as type 2 autoimmune pancreatitis (AIP), is an uncommon subtype of AIP. International Consensus Diagnostic Criteria for IDCP propose that the diagnosis requires pancreatic histology and/or concurrent IBD. We examined our experience with IDCP (type 2 AIP) to assess the appropriateness of these criteria, and identify unique characteristics in patients presenting with acute pancreatitis.
138. Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
作者: Barbara Testoni.;David Durantel.;Fanny Lebossé.;Judith Fresquet.;François Helle.;Francesco Negro.;Maria Francesca Donato.;Massimo Levrero.;Fabien Zoulim.
来源: Gut. 2016年65卷4期672-82页
Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness.
139. The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome.
作者: Garrett Z Ng.;Trevelyan R Menheniott.;Alison L Every.;Andrew Stent.;Louise M Judd.;Yok Teng Chionh.;Poshmaal Dhar.;Jasper C Komen.;Andrew S Giraud.;Timothy C Wang.;Michael A McGuckin.;Philip Sutton.
来源: Gut. 2016年65卷7期1087-99页
The mucin MUC1, best known for providing an epithelial barrier, is an important protective host factor in both humans and mice during Helicobacter pylori pathogenesis. This study aimed to identify the long-term consequences of MUC1 deficiency on H. pylori pathogenesis and the mechanism by which MUC1 protects against H. pylori gastritis.
140. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?
IBS is one of the most common types of functional bowel disorder. Increasing attention has been paid to the causative role of food in IBS. Food ingestion precipitates or exacerbates symptoms, such as abdominal pain and bloating in patients with IBS through different hypothesised mechanisms including immune and mast cell activation, mechanoreceptor stimulation and chemosensory activation. Wheat is regarded as one of the most relevant IBS triggers, although which component(s) of this cereal is/are involved remain(s) unknown. Gluten, other wheat proteins, for example, amylase-trypsin inhibitors, and fructans (the latter belonging to fermentable oligo-di-mono-saccharides and polyols (FODMAPs)), have been identified as possible factors for symptom generation/exacerbation. This uncertainty on the true culprit(s) opened a scenario of semantic definitions favoured by the discordant results of double-blind placebo-controlled trials, which have generated various terms ranging from non-coeliac gluten sensitivity to the broader one of non-coeliac wheat or wheat protein sensitivity or, even, FODMAP sensitivity. The role of FODMAPs in eliciting the clinical picture of IBS goes further since these short-chain carbohydrates are found in many other dietary components, including vegetables and fruits. In this review, we assessed current literature in order to unravel whether gluten/wheat/FODMAP sensitivity represent 'facts' and not 'fiction' in IBS symptoms. This knowledge is expected to promote standardisation in dietary strategies (gluten/wheat-free and low FODMAP) as effective measures for the management of IBS symptoms.
|